Negative Symptom Inventory-Psychosis Risk

📜
Abstract

The Negative Symptom Inventory-psychosis risk (NSI-PR) is a newly developed clinical assessment tool specifically tailored to evaluate negative symptoms in youth and young adults at clinical high risk (CHR) for psychosis. Historically, the field has relied on instruments designed for adults with established schizophrenia, which often fail to capture the nuanced, early-stage deficits seen in prodromal populations. This instrument bridges that gap by offering developmentally appropriate probes and scoring anchors, ensuring that clinicians can accurately detect subtle impairments before the onset of a full psychotic disorder.

Constructed in alignment with the NIMH Consensus Conference on negative symptoms, the NSI-PR evaluates five core domains: anhedonia, avolition, asociality, alogia, and blunted affect. The initial 16-item version was intentionally over-inclusive, incorporating modern social behaviors like texting and distinguishing between internal motivational states and outward behaviors. By utilizing a Semi-structured interview format, the tool allows raters to gather comprehensive clinical information to score each item on a severity continuum.

The development of the NSI-PR represents a critical advancement in early intervention psychiatry. Accurate measurement of negative symptoms in the CHR phase is vital, as these deficits are robust predictors of functional decline and transition to overt psychosis. Through rigorous psychometric evaluation, including item response theory, this initial validation study lays the groundwork for a refined, highly sensitive measure that will enhance both prognostic accuracy and the evaluation of targeted preventative treatments.

🏷
Keywords
psychosis risk
clinical high-risk
negative symptoms
prodrome
clinical interview
psychometrics
schizophrenia
early intervention

📊 Psychometric Scorecard

Items Count
16
Structure
Multidimensional
Validation Country
📍 USA

Authors

👤 Gregory P Strauss
✉ [email protected]
🏛 Department of Psychology, University of Georgia, Athens, GA, USA

👤 Elaine F Walker
🏛 Department of Psychology, Emory University, Atlanta, GA, USA

👤 Andrea Pelletier-Baldelli
🏛 Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA

👤 Nathan T Carter
🏛 Department of Psychology, Michigan State University, East Lansing, MI, USA

👤 Lauren M Ellman
🏛 Department of Psychology and Neuroscience, Temple University, Philadelphia, PA, USA

👤 Jason Schiffman
🏛 Department of Psychological Science, University of California- Irvine, Irvine, CA, USA

👤 Lauren Luther
🏛 Department of Psychology, University of Georgia, Athens, GA, USA

👤 Sydney H James
🏛 Department of Psychology, University of Georgia, Athens, GA, USA

👤 Alysia M Berglund
🏛 Department of Psychology, University of Georgia, Athens, GA, USA

👤 Tina Gupta
🏛 Department of Psychology, Northwestern University, Evanston, IL, USA

👤 Ivanka Ristanovic
🏛 Department of Psychology, Northwestern University, Evanston, IL, USA

👤 Vijay A Mittal
🏛 Department of Psychology, Northwestern University, Evanston, IL, USA

Purpose

The primary purpose of the NSI-PR is to provide a psychometrically sound, developmentally appropriate measure of negative symptoms for individuals at clinical high risk for psychosis. Prior to its development, researchers and clinicians typically adapted adult-focused scales or relied on broad prodromal interviews. However, these approaches frequently resulted in floor effects, skewed data, and poor discriminant validity, as the severity anchors were calibrated for chronic schizophrenia rather than the subtle, emerging deficits characteristic of the prodrome.

By addressing these methodological shortcomings, the NSI-PR fills a critical void in early psychosis research. It equips the field with a specialized tool capable of accurately tracking symptom trajectories and evaluating the efficacy of early interventions. This is particularly important because negative symptoms in the CHR population are highly prevalent and strongly linked to long-term functional disability, making their precise measurement essential for effective preventative care.

Construct

The NSI-PR is grounded in the five-factor model of negative symptoms endorsed by the NIMH Consensus Development Conference. These five domains include anhedonia (reduced ability to experience pleasure), avolition (reduced drive or motivation), asociality (diminished social interest and engagement), alogia (poverty of speech), and blunted affect (reduced emotional expression). Rather than treating negative symptoms as a monolithic construct, this multidimensional framework recognizes the distinct neurobiological and behavioral underpinnings of each domain.

A key theoretical innovation of the NSI-PR is its developmental and contextual sensitivity. For instance, the asociality and avolition domains explicitly differentiate between a patient's internal subjective experience (e.g., desire for social contact) and their actual outward behavior. Furthermore, the scale incorporates contemporary modes of interaction, such as social media and texting, to accurately reflect the social lives of youth and young adults. The construct also integrates affective science principles by separating anticipatory pleasure from consummatory pleasure, providing a highly granular view of hedonic functioning in the psychosis prodrome.

Validity

The validation process for the NSI-PR involved a comprehensive examination of its relationships with existing clinical measures. Convergent validity was established by demonstrating meaningful associations between the NSI-PR and established indices of prodromal negative symptoms, such as the SIPS negative symptom dimension. Furthermore, the scale showed significant relationships with real-world functional outcomes, including social and role functioning metrics (GFS:S and GFS:R) and overall global assessment scores (GAF). This confirms that the NSI-PR captures deficits that genuinely impact a patient's daily life.

Equally important is the scale's discriminant validity, which ensures that the instrument measures negative symptoms specifically, rather than general psychopathology. The researchers confirmed this by showing that NSI-PR scores had only small, non-overlapping correlations with positive symptoms, disorganized symptoms, and general psychological distress. This distinct psychometric profile indicates that the NSI-PR successfully isolates the negative symptom construct from other clinical features commonly seen in clinical high-risk populations.

Convergent & Discriminant Validation Correlations

Reference Instrument Correlation Coefficient (r)
Structured Interview for Psychosis-risk Syndromes (SIPS) negative symptom dimension
Global Functioning Scale: Social (GFS:S)
Global Functioning Scale: Role (GFS:R)
Global Assessment of Functioning (GAF)

Reliability

The psychometric evaluation of the NSI-PR demonstrated robust reliability across multiple dimensions, which is essential for a clinician-administered interview. Internal consistency analyses confirmed that the items within the scale reliably measure the underlying negative symptom constructs without excessive redundancy. This ensures that the various probes and behavioral observations coalesce into a cohesive assessment of the patient's symptom severity.

Given that the NSI-PR relies on rater judgment, inter-rater reliability was a critical focus. The study found strong agreement among different clinicians, both within individual study sites and across the multi-site network, indicating that the scoring anchors and interview prompts are clear and standardized. Additionally, temporal stability was supported through one-year follow-up assessments, demonstrating that the scale can reliably track symptom persistence or change over time, a vital feature for longitudinal research and clinical monitoring.

Factor Analysis

To rigorously evaluate the underlying structure of the NSI-PR, the researchers employed confirmatory multidimensional item response theory (MIRT) utilizing a graded response model. This advanced analytical approach is particularly well-suited for ordinal rating scales, as it evaluates how well each specific response option discriminates between different levels of symptom severity. The team tested competing structural models, including a unidimensional model, a two-factor model (separating motivation/pleasure from diminished expression), and a five-factor model.

The results strongly supported the five-factor structure, perfectly mirroring the theoretical consensus domains of anhedonia, avolition, asociality, alogia, and blunted affect. Beyond confirming the overarching architecture of the scale, the item response theory analyses provided granular insights at the item level. By examining option characteristic curves, the researchers identified specific items that contributed little to the scale's overall information or reliability. This data-driven process justified the removal of underperforming items and suggested that the original seven-point response anchors could be condensed, ultimately guiding the refinement of the tool into a more streamlined 11-item version.

Subscales

Subscale Items Description
Anhedonia Measures diminished capacity to experience anticipatory and past-week pleasure across recreational, role, social, and physical activities.
Avolition Measures reduced drive and motivation, distinguishing between internal experience and outward behavior.
Asociality Measures diminished social interest and engagement, including modern contexts like social media and texting, separating internal desire from behavior.
Alogia Measures poverty of speech and diminished verbal output.
Blunted Affect Measures reduced outward emotional expression.

Instrument

Test Type Semi-structured interview
Format 16 items (initial version), 7-point rating scale (0 to 6)
Scoring Items are rated from 0 (absent) to 6 (extremely severe) based on clinical judgment following a Semi-structured interview.
Language English
Population Adolescents, Clinical patients, Psychiatric patients
Age Group Youth and young adults (Mean age = 21.1 years)
Administration Clinician-administered

Negative Symptom Inventory-Psychosis Risk Items

📋 Items are currently not available

The individual items of this scale are not publicly available. Researchers interested in using this instrument should contact the original authors directly to request the scale materials.

Sample

218 clinical high-risk (CHR) participants recruited from 5 sites. The sample had a mean age of 21.1 years (SD = 3.2) and was 67.4% female. Racial demographics included 53.4% White, 19.0% Black, 14.0% Asian, 6.3% Biracial, 4.1% Central/South American, and 1.4% Native American. 12.8% identified as Hispanic.

Permissions & Test Year

Copyright 2023 by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Test Year: 2023

📄
Cite This Paper

Gregory P Strauss, Elaine F Walker, Andrea Pelletier-Baldelli, Nathan T Carter, Lauren M Ellman, Jason Schiffman, Lauren Luther, Sydney H James, Alysia M Berglund, Tina Gupta, Ivanka Ristanovic, Vijay A Mittal (2023). Negative Symptom Inventory-psychosis risk. schizophrenia bulletin. https://doi.org/10.1093/schbul/sbad038

📄 Download Full-Text PDF

📚
References
50 references
  1. Foussias (2009). Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr Res., 115 (2-3), 333. 🔗 https://doi.org/10.1016/j.schres.2009.09.020
  2. Luther (2020). Clarifying the direction of impact of negative symptoms and neurocognition on prospective work functioning in psychosis: a 20-year longitudinal study. Schizophr Res., 220 232. 🔗 https://doi.org/10.1016/j.schres.2020.03.012
  3. Blanchard (2011). Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull., 37 (2), 291. 🔗 https://doi.org/10.1093/schbul/sbq104
  4. Fusar-Poli (2015). Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull., 41 (4), 892. 🔗 https://doi.org/10.1093/schbul/sbu170
  5. Kirkpatrick (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull., 32 (2), 214. 🔗 https://doi.org/10.1093/schbul/sbj053
  6. Kirkpatrick (2011). The brief negative symptom scale: psychometric properties. Schizophr Bull., 37 (2), 300. 🔗 https://doi.org/10.1093/schbul/sbq059
  7. Kring (2013). The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry., 170 (2), 165. 🔗 https://doi.org/10.1176/appi.ajp.2012.12010109
  8. Galderisi (2021). EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry., 64 (1), e23. 🔗 https://doi.org/10.1192/j.eurpsy.2021.11
  9. Piskulic (2012). negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res., 196 (2-3), 220. 🔗 https://doi.org/10.1016/j.psychres.2012.02.018
  10. Zhang (2020). Clinical subtypes that predict conversion to psychosis: a canonical correlation analysis study from the ShangHai At Risk for Psychosis program. Aust N Z J Psychiatry., 54 (5), 482. 🔗 https://doi.org/10.1177/0004867419872248
  11. Carrión (2016). Duration of attenuated positive and negative symptoms in individuals at clinical high risk: associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res., 81 95. 🔗 https://doi.org/10.1016/j.jpsychires.2016.06.021
  12. Yung (1996). The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry., 30 (5), 587. 🔗 https://doi.org/10.3109/00048679609062654
  13. Miller (2003). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull., 29 (4), 703. 🔗 https://doi.org/10.1093/oxfordjournals.schbul.a007040
  14. Yung (2005). Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry., 39 (11-12), 964. 🔗 https://doi.org/10.1080/j.1440-1614.2005.01714.x
  15. Strauss (2020). A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis. Schizophr Res., 222 104. 🔗 https://doi.org/10.1016/j.schres.2020.04.019
  16. Gur (2015). negative symptoms in youths with psychosis spectrum features: complementary scales in relation to neurocognitive performance and function. Schizophr Res., 166 (1-3), 322. 🔗 https://doi.org/10.1016/j.schres.2015.05.037
  17. Strauss (2018). Preliminary psychometric properties of the brief Negative Symptom Scale in youth at clinical high-risk for psychosis. Schizophr Res., 193 435. 🔗 https://doi.org/10.1016/j.schres.2017.07.051
  18. First (2015). Structured clinical interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV).. 1.
  19. Auther (2006). Global Functioning: Social Scale (GF: Social).
  20. Niendam (2006). Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res., 84 (1), 100. 🔗 https://doi.org/10.1016/j.schres.2006.02.005
  21. Pelletier-Baldelli (2017). Initial development and preliminary psychometric properties of the Prodromal Inventory of negative symptoms (PINS). Schizophr Res., 189 43. 🔗 https://doi.org/10.1016/j.schres.2017.01.055
  22. Strauss (2012). Factor structure of the brief negative symptom scale. Schizophr Res., 142 (1-3), 96. 🔗 https://doi.org/10.1016/j.schres.2012.09.007
  23. Kring (2013). Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol., 9 (1), 409. 🔗 https://doi.org/10.1146/annurev-clinpsy-050212-185538
  24. Strauss (2012). A new perspective on anhedonia in schizophrenia. Am J Psychiatry., 169 (4), 364. 🔗 https://doi.org/10.1176/appi.ajp.2011.11030447
  25. Gruber (2017). Positive emotion specificity and mood symptoms in an adolescent outpatient sample. Cogn Ther Res., 41 (3), 393. 🔗 https://doi.org/10.1007/s10608-016-9796-7
  26. Jhung (2016). Experiential pleasure deficits in the prodrome: a study of emotional experiences in individuals at ultra-high risk for psychosis and recent-onset schizophrenia. Compr Psychiatry., 68 209. 🔗 https://doi.org/10.1016/j.comppsych.2016.04.021
  27. Schlosser (2014). Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. Schizophr Res., 158 (1-3), 52. 🔗 https://doi.org/10.1016/j.schres.2014.06.024
  28. Strauss (2018). Diminished Hedonic response in neuroleptic-free youth at ultra high-risk for psychosis. Schizophr Res Cogn, 12 1. 🔗 https://doi.org/10.1016/j.scog.2017.12.001
  29. Samejima (1969). Estimation of latent ability using a response pattern of graded scores. Psychom Monogr Suppl.,
  30. Chang (2021). The latent structure of negative symptoms in individuals with attenuated psychosis syndrome and early psychosis: support for the 5 consensus domains. Schizophr Bull., 47 (2), 386. 🔗 https://doi.org/10.1093/schbul/sbaa129
  31. Rosseel (2012). An R package for structural equation modeling. J Stat Softw, 48 (2), 🔗 https://doi.org/10.18637/jss.v048.i02
  32. Asparouhov (2016). Structural equation models and mixture models with continuous nonnormal skewed distributions. Struct Equ Model Multidiscip J., 23 (1), 1. 🔗 https://doi.org/10.1080/10705511.2014.947375
  33. Hu (1995). Evaluating model fit. 76.
  34. Haguiara (2021). What is the best latent structure of negative symptoms in schizophrenia? A systematic review. Schizophr Bull Open, 2 (1), sgab013. 🔗 https://doi.org/10.1093/schizbullopen/sgab013
  35. Strauss (2018). The latent structure of negative symptoms in schizophrenia. JAMA Psychiatry, 75 (12), 1271. 🔗 https://doi.org/10.1001/jamapsychiatry.2018.2475
  36. Dollfus (2022). European Validation of the Self-Evaluation of negative symptoms (SNS): a large multinational and multicenter study. Front Psychiatry., 13 826465. 🔗 https://doi.org/10.3389/fpsyt.2022.826465
  37. Havers (2022). The latent structure of negative symptoms in the general population in adolescence and emerging adulthood. Schizophr Bull Open, 3 (1), sgac009. 🔗 https://doi.org/10.1093/schizbullopen/sgac009
  38. Ahmed (2019). Cross-cultural validation of the 5-factor structure of negative symptoms in schizophrenia. Schizophr Bull., 45 (2), 305. 🔗 https://doi.org/10.1093/schbul/sby050
  39. Ang (2019). Validation of the brief negative symptom scale and its association with functioning. Schizophr Res., 208 97. 🔗 https://doi.org/10.1016/j.schres.2019.04.005
  40. Jeakal (2020). Validation of the Brief Negative Symptom Scale in Korean patients with schizophrenia. Asia-Pac Psychiatry, 12 (3), e12382. 🔗 https://doi.org/10.1111/appy.12382
  41. Mucci (2015). The Brief Negative Symptom Scale (BNSS): independent validation in a large sample of Italian patients with schizophrenia. Eur Psychiatry., 30 (5), 641. 🔗 https://doi.org/10.1016/j.eurpsy.2015.01.014
  42. Sun (2021). Validation of the traditional script Chinese version of the brief negative symptom scale. Asian J Psychiatry., 55 102522. 🔗 https://doi.org/10.1016/j.ajp.2020.102522
  43. Tam (2021). Latent structure of self-report negative symptoms in patients with schizophrenia: a preliminary study. Asian J Psychiatry., 61 102680. 🔗 https://doi.org/10.1016/j.ajp.2021.102680
  44. Turner (2021). ENIGMA + COINSTAC: improving findability, accessibility, interoperability, and re-usability. Neuroinformatics, 21 261.
  45. Ahmed (2022). Two factors, five factors, or both? External validation studies of negative symptom dimensions in schizophrenia. Schizophr Bull., 48 (3), 620. 🔗 https://doi.org/10.1093/schbul/sbab148
  46. Strauss (2019). Network analysis reveals the latent structure of negative symptoms in schizophrenia. Schizophr Bull., 45 (5), 1033. 🔗 https://doi.org/10.1093/schbul/sby133
  47. Gold (2020). Enhancing psychosis risk prediction through computational cognitive neuroscience. Schizophr Bull., 46 (6), 1346. 🔗 https://doi.org/10.1093/schbul/sbaa091
  48. Cannon (2016). An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry., 173 (10), 980. 🔗 https://doi.org/10.1176/appi.ajp.2016.15070890
  49. Fusar-Poli (2017). Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. JAMA Psychiatry, 74 (5), 493. 🔗 https://doi.org/10.1001/jamapsychiatry.2017.0284
  50. Zhang (2019). Prediction of psychosis in prodrome: development and validation of a simple, personalized risk calculator. Psychol Med., 49 (12), 1990. 🔗 https://doi.org/10.1017/S0033291718002738

Cite this article

Mohammed looti (2026). Negative Symptom Inventory-Psychosis Risk. PSYCHOLOGICAL SCALES. Retrieved from https://scales.arabpsychology.com/s/negative-symptom-inventory-psychosis-risk/

Mohammed looti. "Negative Symptom Inventory-Psychosis Risk." PSYCHOLOGICAL SCALES, 12 Aug. 2026, https://scales.arabpsychology.com/s/negative-symptom-inventory-psychosis-risk/.

Mohammed looti. "Negative Symptom Inventory-Psychosis Risk." PSYCHOLOGICAL SCALES, 2026. https://scales.arabpsychology.com/s/negative-symptom-inventory-psychosis-risk/.

Mohammed looti (2026) 'Negative Symptom Inventory-Psychosis Risk', PSYCHOLOGICAL SCALES. Available at: https://scales.arabpsychology.com/s/negative-symptom-inventory-psychosis-risk/.

[1] Mohammed looti, "Negative Symptom Inventory-Psychosis Risk," PSYCHOLOGICAL SCALES, vol. X, no. Y, ص Z-Z, August, 2026.

Mohammed looti. Negative Symptom Inventory-Psychosis Risk. PSYCHOLOGICAL SCALES. 2026;vol(issue):pages.

Related terms:

  1. Premenstrual Symptom Screening Tool for Working Women
  2. Hopkins Symptom Checklist (HSCL-58)
  3. PTSD Symptom Scale Interview (PSS-I)
  4. Pediatric Symptom Checklist (PSC-35)
  5. Child PTSD Symptom Scale (CPSS)
  6. Four-Dimensional Symptom Questionnaire (4DSQ)
  7. Condensed Memorial Symptom Assessment Scale (CMSAS)
  8. Y-BOCS Symptom Checklist (Y-BOCS-SC)
  9. International Prostate Symptom Score
  10. Autism Symptom Dimensions Questionnaire (ASDQ)
× Figure
PDF
Scroll to Top